(Alliance News) - Healthcare company investor Syncona Ltd on Wednesday noted that its portfolio company Freeline Therapeutics PLC trimmed its loss for the first quarter of 2022.
Freeline's pretax loss narrowed to USD26.7 million in the three months to March 31, from USD34.9 million a year ago. Total operating expenses fell to USD28.2 million from USD33.9 million, mainly due to a decrease in spending on FLT210, a former product candidate for the treatment of Haemophilia A.
Freeline is a Stevenage, England-based biotechnology company focused on liver directed gene therapies for bleeding disorders and other chronic diseases.
The firm is expected to fully enrol in a Phase 1/2 trial of clinical programmes in Haemophilia B, Gaucher disease and Fabry disease by the end of the third quarter of 2022. Phase 3 start-up activities could start in the first half of 2023, Syncona explained.
Syncona shares were 0.2% higher at 170.40 pence each in London on Wednesday morning.
By Tom Budszus; tombudszus@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Syncona (SYNC)